PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26023F0110Pegloticase (krystexxa) - PUGET SOUND VAMC — Horizon Therapeutics Usa, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Dec 30, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)

Awarding office

Horizon Therapeutics Usa, Inc

Recipient

Dec 30, 2023

PoP end

$426K

Obligated

$431K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Horizon Therapeutics Usa, Inc — $90

Contract facts

Federal

Contract number36C26023F0110

Also listed as36C260-23-F-0110

Also listed as36F79719D0224-36C26023F0110

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentHorizon Therapeutics Usa, Inc

CAGE6TDL9

UEISK1UK7S74GB3

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79719D0224

Place of performanceSEATTLE WA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startDec 31, 2022

PoP end (current)Dec 30, 2023

Obligated$426K

Current value$431K

Potential value$431K

PEGLOTICASE (KRYSTEXXA) - PUGET SOUND VAMC is a federal award for 260-Network Contract Office 20 (36C260) held by Horizon Therapeutics Usa, Inc. Estimated value $431K ($426K obligated). Current period of performance ends Dec 30, 2023. Last award drew 1 bidder. Place of performance: SEATTLE WA.

PEGLOTICASE (KRYSTEXXA) - PUGET SOUND VAMC

Recompete timing

Public

● Past PoP end (965 days ago)

Current PoP ended Dec 30, 2023 (965 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26023F0110?

36C26023F0110 (Pegloticase (krystexxa) - PUGET SOUND VAMC) is a 260-Network Contract Office 20 (36C260) award with a potential value of $431K, currently held by Horizon Therapeutics Usa, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-23-F-0110?

36C260-23-F-0110 is the dashed form of PIID 36C26023F0110 (Pegloticase (krystexxa) - PUGET SOUND VAMC), held by Horizon Therapeutics Usa, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26023F0110?

260-Network Contract Office 20 (36C260) awarded 36C26023F0110 to Horizon Therapeutics Usa, Inc (potential $431K).

Who is the incumbent on 36C26023F0110?

Horizon Therapeutics Usa, Inc is the incumbent. The current period of performance ends Dec 30, 2023.

When does Horizon Therapeutics Usa, Inc’s 36C26023F0110 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 30, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jan 19, 2024 · refreshed monthly